Published Studies Related to Ortho Tri-Cyclen Lo (Norgestimate / Ethinyl Estradiol)
Well-designed clinical trials related to Ortho Tri-Cyclen Lo (Norgestimate / Ethinyl Estradiol)
Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. [2006.12]
Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. [2005.09]
Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. [2003.08]
Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. [2003.07]
Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. [2003.06]
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. [2001.06]
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. [1997.11]
Well-designed clinical trials possibly related to Ortho Tri-Cyclen Lo (Norgestimate / Ethinyl Estradiol)
Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. [2009.12]
Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. [1999.08]
Other research related to Ortho Tri-Cyclen Lo (Norgestimate / Ethinyl Estradiol)
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. [2011]
A norgestimate-containing oral contraceptive: review of clinical studies. [1992.10]
The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women. [1992.06]
Clinical experience with a new norgestimate-containing oral contraceptive. [1992]
Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. [1992]
Clinical experience with a new norgestimate-containing oral contraceptive. [1991]
|
